This week's innovators to know roundup includes Roberta Schwartz of Houston Methodist, Jani Tuomi of imaware, and Jill Chapman of Insperity. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators across industries — including some with COVID-19 news.

Roberta Schwartz, executive vice president of Houston Methodist Hospital

Roberta Schwartz is leading the innovation initiative at Houston Methodist. Courtesy of Houston Methodist

Houston Methodist and its Center for Innovation — led by Roberta Schwartz, executive vice president of Houston Methodist Hospital — has been in the innovation news around Houston in a few ways. First, the health care innovation hub was recognized with the Listies award for corporate innovation and Schwartz accepted the award on behalf of her team.

Last week, Houston Methodist was announced to be on the short list for the COVID-19 vaccine being developed and distributed by Pfizer.

And finally, Schwartz shared details about a new voice technology the hospital has implemented into their operating rooms. The technology uses ambient listening to help surgeons operate hands free from typing or note taking and focus on their patient. Read more.

Jani Tuomi, co-founder of imaware

Jani Tuomi, co-founder of imaware, joins the Houston Innovators Podcast to discuss his company's, early disease screening, COVID-19 testing, and more. Photo courtesy of imaware

As COVID-19 was emerging as an international threat across January and February, Jani Tuomi and his team at imaware — a Houston health tech startup providing at-home testing for chronic conditions — quickly jumped on a way to provide at-home coronavirus testing.

"Right away there was an amazing reception," Tuomi says, adding that big companies were looking to provide their employees on-site training. "There was way more need for testing than supply was available."

Imaware formed strategic partnerships with other Texas companies, including Austin-based startup Wheel — the telemedicine partner. Basically, users take a quick assessment online and if they are high risk, a health care worker is deployed to the patient's site to conduct the test. Once finished, the lab analyzes the sample and telemedicine professionals reach out with results and next steps. Read more and stream the podcast.

Jill Chapman, senior performance consultant with Insperity

Jill Chapman is a senior performance consultant with Insperity. Photo courtesy of Insperity

With Thanksgiving in the rearview, the holiday season is in full swing. And, as some companies in Houston have either partially or completely resumed in-office workdays, businesses might also be looking to spread some holiday cheer around the workspace. Jill Chapman, a senior performance consultant with Insperity, shared in a guest column for InnovationMap her ideas for safe virtual and in-person festivities.

"Business leaders should consider hosting holiday celebrations that honor their employees and align with their ongoing safety protocols," she writes. "For companies that continue to conduct in-person business, holiday celebrations may be safely held outside in Houston's temperate climate. For companies that plan to proceed with virtual celebrations, think outside the box for developing an event that colleagues will enjoy." Read more.

Jani Tuomi, co-founder of imaware, joins the Houston Innovators Podcast to discuss his company's, early disease screening, COVID-19 testing, and more. Photo courtesy of imaware

Houston startup is fostering the future of chronic disease prevention and treatment

HOUSTON INNOVATORS PODCAST EPISODE 59

A family illness got Jani Tuomi thinking — why does treatment of chronic conditions seem like too little, too late? When his brother fell ill, he wondered if more could have been done preemptively.

"The doctors were really good at treating him — but the question I had was why couldn't we have screened for this in advance," Tuomi says on this week's episode if the Houston Innovators Podcast.

He entertained his intuition and started researching, which transitioned into co-founding imaware, a digital health platform that focuses on early identification of chronic conditions — such as diabetes, heart disease, autoimmune issues. What Tuomi and his team found was that these chronic diseases come with biomarkers you can measure before you see symptoms.

Now, imaware exists to provide at-home blood tests for everything from heart health and allergies to thyroid and arthritis screening. And, as COVID-19 was emerging as an international threat across January and February, Tuomi says his team quickly jumped on a way to provide at-home coronavirus testing.

"Right away there was an amazing reception," Tuomi says, adding that big companies were looking to provide their employees on-site training. "There was way more need for testing than supply was available."

Imaware formed strategic partnerships with other Texas companies, including Austin-based startup Wheel — the telemedicine partner. Basically, users take a quick assessment online and if they are high risk, a health care worker is deployed to the patient's site to conduct the test. Once finished, the lab analyzes the sample and telemedicine professionals reach out with results and next steps.

Business for imaware has been booming, and Tuomi has had to scale his business virtually amid the pandemic. Imaware also has an office in Austin, which is focused on the digital side of business.

Looking forward, Tuomi says he's planning on zooming in on the various ways patients were affected by COVID-19, and this summer imaware formed a partnership with Texas A&M University researchers to begin that investigation. Tuomi says he doesn't expect the finalized data until early next year, but what he says the research seems to show is people reacted differently to the disease, and those reactions seem to relate to underlying or chronic conditions — the same conditions imaware has developed early testing for.

"Before COVID, imaware's mission was to identify individuals with chronic conditions earlier, so we're going to double down on our tests," Tuomi says.

Tuomi shares more about the lessons learned from turning around the COVID test so quickly, as well as some of the ways the pandemic has affected the health care industry as a whole. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Houston-based imaware, which has an at-home COVID-19 testing process, is working with Texas A&M University on researching how the virus affects the human body. Getty Images

Houston health tech startup with at-home COVID-19 test teams up with Texas university for research

be aware

An ongoing medical phenomenon is determining how COVID-19 affects people differently — especially in terms of severity. A new partnership between a Houston-based digital health platform and Texas A&M University is looking into differences in individual risk factors for the virus.

Imaware, which launched its at-home coronavirus testing kit in April, is using its data and information collected from the testing process for this new study on how the virus affects patients differently.

"As patient advocates, we want to aid in the search to understand more about why some patients are more vulnerable than others to the deadly complications of COVID-19," says Jani Tuomi, co-founder of imaware, in a press release. "Our current sample collection process is an efficient way to provide longitudinal prospectively driven data for research and to our knowledge, is the only such approach that is collecting, assessing, and biobanking specimens in real time."

Imaware uses a third-party lab to conduct the tests at patients' homes following the Center for Disease Control's guidelines and protocol. During the test, the medical professional takes additional swabs for the study. The test is then conducted by Austin-based Wheel, a telemedicine group.

Should the patient receive positive COVID-19 results, they are contacted by a representative of Wheel with further instructions. They are also called by a member of a team led by Dr. Rebecca Fischer, an infectious disease expert and epidemiologist and laboratory scientist at the Texas A&M University School of Public Health, to grant permission to be a part of the study.

Once a part of the study, the patient remains in contact with Fischer's team, which tracks the spread and conditions of the virus in the patient. One thing the researchers are looking for is the patients' responses to virus complications caused by an overabundance of cytokines, according to the press release. Cytokines are proteins in the body that fight viruses and infections, and, if not working properly, they can "trigger an over-exuberant inflammatory response" that can cause potentially deadly issues with lung and organ failure or worse, per the release.

"We believe strongly in supporting this research, as findings from the field can be implemented to improve clinical processes-- helping even more patients," says Wheel's executive medical director, Dr. Rafid Fadul.

Houston-based Imaware has launched at-home testing that can identify if the patient has — or even had — the coronavirus. Photo via imaware.health

Houston health tech startup launches game-changing, at-home coronavirus testing

be aware

Politicians, scientists, public health officials, and others continue to stress the need for widespread testing to tame the spread of the novel coronavirus.

Houston-based startup Imaware, an at-home health testing platform, recently rolled out an at-home coronavirus test for high-risk people, such as someone with both a fever and recent exposure to someone infected with the virus. Now, it's gearing up to offer an at-home test designed to spot the presence of coronavirus antibodies in your blood.

Experts view antibody testing as a key to corralling the virus and rebooting the virus-crushed U.S. economy. However, some skeptics fear the benefits of antibody testing are being oversold.

As explained by Health.com, a nasal swab test can detect a coronavirus infection. But a blood test can pinpoint whether a person has been exposed to the novel coronavirus, which causes the COVID-19 respiratory illness, and might now be immune to it.

Jani Tuomi, co-founder of Imaware, says his company is working with the U.S. Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) on approval of Imaware's antibody test. The in-home blood test might be available as early as May.

"We're still trying to make sure that everything checks out and validation is completed," Tuomi says, "but it looks like it's headed in the right direction."

In early April, the FDA approved the first test in the U.S. to detect coronavirus antibodies.

Tuomi says the process for Imaware's coronavirus antibody test will be similar to the one for the coronavirus detection test. Both tests, for instance, will be administered by licensed clinicians.

Here's how the basic test works.

To request a coronavirus test, someone completes a 10-question assessment at imaware.health. Austin-based startup Wheel, Imaware's telemedicine partner, created the online assessment.

Someone is given the go-ahead for testing if, as determined by a licensed health care professional, he or she falls into certain risk categories. For instance, somebody who's been exposed to a person with coronavirus and is over 60 years old would be approved for a test.

If health insurance covers the test or a patient pays for it entirely out of pocket, the test costs $135. (The home-based antibody test will cost about $120 to $125.) Public health agencies, including the Houston Health Department, can authorize a test for someone who can't afford it.

A trained health care professional goes to a patient's home to collect a test sample (by taking a nasal swab for the coronavirus test or drawing blood for the antibody test). A CDC-authorized lab then tests the sample. If needed, a board-certified health care professional can provide post-diagnosis care.

Results of a coronavirus test typically are available within three days. Tuomi says he hopes the results window for the test can be narrowed to between one and two days by the end of April.

"As a patient-advocate company, we are uniquely poised to be part of the testing shortage solution in Texas," Tuomi says in a March 23 release announcing the Imaware coronavirus swab test. "Our online platform, telemedicine partner, and in-home sample collection empower patients to take control of their health and access COVID-19 testing from the comfort of home."

Founded in 2018, Imaware employs 14 people. Others involved in the testing process, such as in-home testing clinicians and telemedicine experts, work for third-party partners. As the company adds to its testing lineup, Tuomi envisions the workforce rising to around 30 to 40 people by the end of 2020.

Earlier this year, Imaware (whose legal name is Microdrop LLC) had concentrated on home-based remote screening and monitoring for conditions like celiac disease and heart disease. But once it became clear that the coronavirus pandemic would be striking the U.S., the company shifted to coronavirus testing and, now, to antibody testing.

Before Imaware jumped into coronavirus testing, Tuomi performed a swab test on himself and realized that it wasn't feasible for anyone to do self-testing. On top of that, evidence surfaced that self-collection of test samples was producing a lot of false-negative results, he says. Subsequently, the federal government blocked self-testing for the coronavirus.

Today, health care professionals handle Imaware's at-home coronavirus testing and will handle the at-home antibody testing. The testing initially launched in Houston then expanded to the rest of Texas.

Tens of thousands of people have done coronavirus self-assessments through Imaware's online tool, Tuomi says. Far fewer people — in the hundreds — have actually fallen into high-risk categories based on the self-assessments and then have qualified for testing.

Tuomi says that as testing capabilities grow, Imaware will be able to accommodate people who fit into medium-risk coronavirus categories. Also, the company plans to offer its coronavirus test in states that neighbor Texas. Imaware hopes to provide its antibody test throughout the U.S.

In tandem with the public testing, Imaware teamed up with Austin-based energy tech startup RigUp to enable daily coronavirus screening at oil and gas jobsites. Imaware and RigUp are piloting the screening with several RigUp customers; they hope it eventually can be supplied nationwide.

"A cornerstone of the Imaware solution is the patient-centric approach offering superior telemedicine care from diagnosis to recovery," Tuomi says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

10 Houston billionaires make Forbes' list of richest Americans in 2025

The Rich List

America's wealthiest billionaires are $1.2 trillion richer in 2025, bringing their collective worth to a staggering $6.6 trillion. And Houston's own Richard Kinder has become the richest billionaire in the city, according to the new Forbes 400.

The Kinder Morgan chairman is the 11th richest Texas resident and ranks as the 108th richest American. Kinder also dethroned Tilman Fertitta to claim the title as the wealthiest Houstonian.

The annual Forbes 400 list is a definitive ranking of the wealthiest Americans, using interviews, financial data, and documentation provided by billionaires and their companies.

Kinder's wealth

The publication estimates Kinder's net worth at $10.6 billion, up from $8.1 billion last year. He also appears among Forbes' separate list of the richest billionaires in the world.

"It’s been a year unlike any we’ve seen in the four decades we’ve tracked America’s billionaire class,” said Forbes senior editor Chase Peterson-Withorn in a press release. "The super-rich at the very top are richer than ever — and between the White House and the booming stock market, they’re as powerful as they’ve ever been."

Kinder, 80, co-founded oil and gas pipeline firm Kinder Morgan in 1997, which is now known as one of the largest American energy infrastructure companies. He stepped down as CEO in 2015, though he still chairs the board of directors.

Kinder and his wife, Nancy, also founded Houston-based nonprofit the Kinder Foundation in 1997. The organization provides "major gifts to public causes with the intention of helping people realize healthy and rewarding lives," according to its website.

In May 2025, the Kinders pledged $150 million to Texas Children's Hospital and MD Anderson to create the Kinder Children's Cancer Center.

"Our philanthropic efforts center on supporting transformational projects in Houston, and this initiative exemplifies that mission in every way," said Kinder in a press release. "We were deeply impressed by the extraordinary leadership and unwavering commitment of both UT MD Anderson and Texas Children’s to pursue a bold, collaborative model of care. It is a rare and powerful moment when two leading organizations come together to create something entirely new – something capable of reshaping the future of pediatric cancer care."

The richest Houstonians

In all, 43 Texas billionaires made it on the 2025 Forbes 400 list, and 10 are based in the Houston metro.

Hospitality honcho Fertitta, 68, is the second-richest billionaire in Houston, and his net worth has jumped from $10.1 billion last year to $11 billion in 2025. He owns the Golden Nugget Casinos, the Houston Rockets, Texas-based restaurant and entertainment company Landry's, and also serves as the U.S. Ambassador to Italy.

"Serving as President Trump's ambassador to Italy 'is a real job,' says Fertitta, who personally oversaw the renovation of Villa Taverna, the ambassador's residence in Rome," Forbes wrote in his profile.

Fertitta most recently put his ritzy 250-foot-long superyacht on the market for about $192 million, with Forbes saying he "has a bigger one on order."

Here's how the rest of Houston's billionaires fared on this year's list:

  • Oil tycoon Jeffery Hildebrand ties for No. 123 nationally with an estimated net worth of $10 billion. Last year: $7.6 billion.
  • Toyota mega-dealer Dan Friedkin ranks 128th nationally with an estimated net worth of $9.7 billion. Last year: $7.6 billion.
  • Houston pipeline heir Randa Duncan Williams ranks 130th with an estimated net worth of $9.5 billion. Fellow pipeline heirs Dannine Avara and Milane Frantz tie for 135th nationally. Each has an estimated net worth of $9.4 billion. Scott Duncan ranks No. 141 with a $9.2 billion estimated net worth.
  • Houston Texans owner Janice McNair ranks 201st nationally with an estimated net worth of $7.3 billion. Last year: $6.2 billion.
  • Energy exploration chief exec George Bishop of The Woodlands ranks No. 325 with an estimated net worth of $4.7 billion. Last year: $5 billion.

Richest billionaires elsewhere in Texas

The richest person in America in 2025 is none other than Austin-based Elon Musk. Musk, 54, saw his net worth skyrocket to $428 billion this year, or $184 billion more than his 2024 net worth. He claimed the No. 1 spot for the fourth time.

Walmart heiress Alice Walton of Fort Worth was dubbed the wealthiest woman in America for 2025. Walton, 75, simultaneously holds the title as the richest woman in the world. Forbes estimates Walton's net worth at $106 billion (up from $89.2 billion last year) and proclaims her as the first female centibillionaire (a person with a 12-digit fortune) in America. Now that's wealth.

"Tariffs. Inflation. Slowing employment. None of it has hit the fortunes of America’s billionaires," Forbes said. "A decade ago, when it took $1.7 billion to make The Forbes 400, a net worth of $3.8 billion was comfortably within the top half of the ranking — now that lofty sum is the minimum required."

---

This article originally appeared on CultureMap.com.

Rice leads Texas colleges on LinkedIn's first-ever career success ranking

honor roll

Houston’s Rice University leads the Texas schools in LinkedIn’s first-ever ranking of the 50 best U.S. colleges for long-term career success.

Rice appears at No. 31 in the ranking. Southern Methodist University, located in the Dallas suburb of University Park, lands at No. 37 and the University of Texas at Austin shows up at No. 46.

LinkedIn, a career networking site, says the ranking is based on exclusive data about alumni, such as job placement rates, advancement into senior-level jobs, post-graduate formation of startups, and pre-graduation internships.

“A four-year bachelor’s degree is a significant investment of time and money, especially as tuition costs rise and the job market shifts,” the LinkedIn report says. “For millions of Americans, the return on investment is worth it. Those who earn the degree can see an enduring impact on their earning potential and overall career trajectory.”

Where someone earns a degree can have an even bigger impact, according to LinkedIn, as graduates of top programs often land jobs more rapidly, build strong professional networks, and rise to leadership roles more quickly.

“Long-term success isn’t just about landing a great first job; it’s about sustained career growth and opportunity years after graduation,” Andrew Seaman, senior editor-at-large for jobs and career development at LinkedIn News, told Fortune. “For this list, that means looking at how well a school sets alumni up for the long haul.”

Here’s a breakdown of some of the data about the three Texas schools on the LinkedIn list:

Rice University

  • Top industries of graduates: Technology, business consulting, higher education
  • Top post-graduation destinations: Houston, San Francisco Bay Area, New York City
  • Notable skills: MATLAB programming language, engineering design, data science

Southern Methodist University

  • Top industries of graduates: Financial services, business consulting
  • Top post-graduation destinations: Dallas, New York City, Los Angeles
  • Most notable skills: AMPL programming language, Avid iNews content creation system, data science

University of Texas at Austin

  • Top industries of graduates: Technology, medical practices, advertising
  • Top post-graduation destinations: Austin, Dallas, Houston
  • Most notable skills: SOLIDWORKS computer-aided design software, architecture, Avid Media Composer video editing software

TMC lands $3M grant to launch cancer device accelerator

cancer funding

A new business accelerator at Houston’s Texas Medical Center has received a nearly $3 million grant from the Cancer Prevention and Research Institute of Texas.

The CPRIT grant, awarded to the Texas Medical Center Foundation, will help launch the Accelerator for Cancer Medical Devices. The accelerator will support emerging innovators in developing prototypes for cancer-related medical devices and advancing them from prototype to clinical trials.

“The translation of new cancer-focused precision medical devices, often the width of a human hair, creates the opportunity to develop novel treatments for cancer patients,” the accelerator posted on the CPRIT website.

Scientist, consultant, and entrepreneur Jason Sakamoto, associate director of the TMC Center for Device Innovation, will oversee the accelerator. TMC officials say the accelerator builds on the success of TMC Innovation’s Accelerator for Cancer Therapeutics.

Each participant in the Accelerator for Cancer Medical Devices program will graduate with a device prototype, a business plan, and a “solid foundation” in preclinical and clinical strategies, TMC says. Participants will benefit from “robust support” provided by the TMC ecosystem, according to the medical center, and “will foster innovation into impactful and life-changing cancer patient solutions in Texas and beyond.”

In all, CPRIT recently awarded $27 million in grants for cancer research. That includes $18 million to attract top cancer researchers to Texas. Houston institutions received $4 million for recruitment:

  • $2 million to the University of Texas MD Anderson Cancer Center to recruit Rodrigo Romero from Memorial Sloan Kettering Cancer Center in New York City
  • $2 million to MD Anderson to recruit Eric Gardner from Weill Cornell Medicine in New York City

A $1 million grant also went to Baylor College of Medicine researcher Dr. Akiva Diamond. He is an assistant professor at the medical college and is affiliated with Baylor’s Dan L. Duncan Comprehensive Cancer Center.